RxDoctor Payments DataLook up a doctor →

Ralph Boccia, MD

Hematology & Oncology · Bethesda, MDNPI 1881663284

Payments from drug & device makers

$12,116,882in general payments, 2019–2025

Across 4,546 payments — averaging $2665.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2.1M
  • AbbVie$1.1M
  • Takeda Pharmaceuticals U.S.A., Inc.$1M
  • Daiichi Sankyo Inc.$763K
  • Incyte Corporation$723K
  • Bristol Myers Squibb$672K
  • plus $5.7M from 54 others
$19,218in research payments, 2019–2025

Across 34 payments — averaging $565.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dr.reddy's Laboratories,inc.$11K
  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • AbbVie$3K
  • Sanofi$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)213$2,141,676
AbbVie282$1,070,574
Takeda Pharmaceuticals U.S.A., Inc.149$1,018,555
Daiichi Sankyo Inc.192$763,298
Incyte Corporation527$722,894
Bristol Myers Squibb174$671,596
Amgen194$646,154
Genentech, Inc.65$590,090
E.r. Squibb & Sons, L.L.C.234$477,662
GSK25$466,494
Seagen Inc.90$331,463
Janssen Scientific Affairs, LLC9$231,390
Johnson & Johnson(3 entities)278$218,434
EMD Serono, Inc.83$213,484
Alkermes, Inc.33$198,503
Astrazeneca UK Limited6$169,382
Karyopharm Therapeutics Inc.61$162,353
Sobi, Inc106$159,971
Fennec Pharmaceuticals, Inc.42$156,504
Beigene USA, Inc.99$139,519
Sanofi115$136,301
Regeneron Healthcare Solutions, Inc.116$131,455
Rigel Pharmaceuticals, Inc.101$116,196
Pharmacosmos Therapeutics Inc.74$102,198
TG Therapeutics, Inc.59$95,513
G1 Therapeutics, Inc.48$69,405
Dova Pharmaceuticals35$67,820
Genmab U.S., Inc.56$63,388
Napo Pharmaceuticals Inc15$53,828
Janssen Research & Development, LLC5$49,426
Taiho Oncology, Inc.46$46,569
Novartis103$43,641
Regeneron12$42,722
Sanofi US Services Inc.8$39,686
Coherus Oncology, Inc.35$37,465
Puma Biotechnology, Inc.43$34,462
Pfizer80$34,395
Aadi Bioscience, Inc.1$33,500
Secura Bio, Inc.11$33,467
Genentech USA, Inc.45$32,523
Morphosys AG10$24,615
Epizyme, Inc.19$24,504
Jazz Pharmaceuticals Inc.15$21,574
Dr.reddy's Laboratories,inc.19$20,984
Geron Corporation22$20,099
Stemline Therapeutics Inc.15$15,808
Beone Medicines USA, Inc.15$14,943
Lilly USA, LLC29$14,058
Beigene, Ltd.2$13,896
Blueprint Medicines Corporation24$12,876
Ipsen Biopharmaceuticals, Inc13$12,004
American Regent1$11,902
Principia Biopharma Inc.8$11,400
CTI Biopharma Corp.6$10,199
Mirati Therapeutics, Inc.13$10,051
Veracyte, Inc.3$9,750
F. Hoffmann-la Roche AG7$9,237
Verastem, Inc.5$7,386
ADC Therapeutics America, Inc.5$5,131
Novocure Inc.4$4,903

How this compares

$12,116,882 in reported general payments places this provider in the 95th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland →

Medicare billing

Part B allowed, 2024
$5,794,598
Medicare patients
894
Services billed
329,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Bethesda

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →